ArticleHuman molecular genetics2025
A novel splicing variant in TECTA associated with prelingual autosomal dominant nonsyndromic hearing loss via dominant-negative effect.
Article in Human molecular genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protocol for the purification and culture of primary retinal ganglion cells and development of common pathological models.Journal of molecular histology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
The TECTA gene encodes α-tectorin, the major non-collagenous glycoprotein of the tectorial membrane, and plays a critical role in intracochlear sound transmission. Unsurprisingly, mutations in TECTA underlie hearing loss in both mice and humans. Two forms of hearing loss are linked to TECTA mutations: DFNA8/12 (autosomal dominant) and DFNB21 (autosomal recessive). Using a combination of clinical examination, pedigree analysis, exome sequencing, and functional studies, we identified a novel aberrant splicing variant, c.5999G > A (p.Gly2000Glu), in TECTA as the cause of autosomal dominant hearing loss in five-generation kindred of Chinese descent and provided prenatal diagnosis for the family. To investigate whether the variant acts via a a dominant-negative effect, consistent with pathogenesis observed in mouse models, we performed in vivo RNA analysis. Our data demonstrated that the variant altered RNA splicing, specifically causing aberrant splicing of exon 20 and resulting in two in-frame deletions. Quantitative real-time polymerase chain reaction revealed no significant reduction in mRNA levels in lymphoblasts derived from individuals harboring the TECTA c.5999G > A (p.Gly2000Glu) variant or the TECTA c.5383 + 6 T > A splicing variant, previously shown to result in exon 16 skipping. This study confirms the involvement of an aberrant splicing mutation in TECTA in autosomal dominant nonsyndromic hearing loss, expands the mutational landscape of DFNA8/12 to include coding variants that alter RNA splicing, and underscores the importance of investigating splicing effects of coding variants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.